On Wednesday, Koronis Pharmaceuticals, Inc. announces the initiation of a Phase 1B clinical trial of KP-1461, an anti-viral therapeutic, in HIV-positive patients. The objectives of the trial are to evaluate the safety, toxicity, pharmacokinetic profile and initial clinical activity of KP-1461.

Unlike currently approved anti-HIV drugs that work to inhibit the HIV-virus by suppressing its replication, KP-1461 is designed to generate a high rate of mutation that is lethal to the virus

The Department of Health and Human signs a deal that could include an order for 100,000 doses of a drug to treat anthrax once it has entered the body.

The biotech company Human Genome Sciences says Monday it has signed a contract with HHS to provide a 10 gram sample of its drug ABthrax for $1.8 million for the agency to study

A new study finds more than a third of U.S. pediatricians surveyed say they would tell families who refuse all vaccinations for their children to look elsewhere for care.

The report says that, "In the case of parents refusing specific vaccines, 82 (28 percent of the doctors) said that they would ask the family to seek care elsewhere; for refusal of all vaccines, 116 (39 percent) of pediatricians said they would refer the family" to another doctor

A new study finds more than a third of U.S. pediatricians surveyed say they would tell families who refuse all vaccinations for their children to look elsewhere for care.

The report says that, "In the case of parents refusing specific vaccines, 82 (28 percent of the doctors) said that they would ask the family to seek care elsewhere; for refusal of all vaccines, 116 (39 percent) of pediatricians said they would refer the family" to another doctor

Regulators are changing the look of prescription drug labels.

Rules outlining a new format will be issued soon, said Dr. Scott Gottlieb, the Food and Drug Administration deputy commissioner for medical and scientific affairs